U.S. pharma large copyright scrapped two experimental weight loss products last calendar year—a at the time-day by day pill, lotiglipron, on account of elevated liver enzymes plus a two times-day by day tablet, danuglipron, resulting from robust Unwanted side effects—but CEO Albert Bourla has claimed the company is decided to “Perform and acq